Publications by authors named "Tetsuji Hashida"
Article Synopsis
- Tacrolimus was approved in Japan in 2013 for treating interstitial lung disease in patients with polymyositis and dermatomyositis.
- A postmarketing surveillance study by Kuwana et al showed positive interim results after two years.
- The study found that immunosuppressive regimens containing tacrolimus were well tolerated by patients with PM/DM-associated ILD.
Objective: To assess the long-term safety and effectiveness of tacrolimus as maintenance therapy in patients with lupus nephritis (LN) receiving treatment in real-world clinical settings in Japan.
Methods: An open-label, noncomparative, observational, prospective postmarketing surveillance study was conducted in 1395 patients with LN receiving maintenance treatment with tacrolimus at 278 medical institutions across Japan over a period of 10 years. Tacrolimus continuation rate and cumulative incidence of adverse drug reactions (ADRs), relapse, progression to renal failure, and progression to dialysis were calculated using Kaplan-Meier analysis.